✨ Free AI Report
FibroGen, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research FibroGen, Inc.
Company Research

FibroGen, Inc.: Business Overview, Financials & Competitive Analysis

FibroGen, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Refocused biotech player pivoting to oncology with extended cash runway and first-in-class ADC assets, though facing execution risk in clinical development. FibroGen faced setbacks with late-stage trials for pamrevlumab in pancreatic cancer failing to meet primary endpoints, leading to program termination and a 75% reduction in U.S. workforce. However, the.

What is FibroGen, Inc.'s industry? FibroGen, Inc. (fibrogen.com) operates in Biopharmaceutical - Oncology and Hematology. AskCyborg classifies FibroGen, Inc. under Biopharmaceutical - Oncology and Hematology in its company registry.

FibroGen, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company focuses on anemia, fibrotic disease, and cancer using proprieta...

6/ 10Solid

Cyborg Score thesis

Refocused biotech player pivoting to oncology with extended cash runway and first-in-class ADC assets, though facing execution...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology and Hematology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest FibroGen, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for FibroGen, Inc.

AskCyborg analysts argue the bull and bear cases for FibroGen, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
FibroGen, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

FibroGen, Inc. Overview

Pro stress-test →

FibroGen, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company focuses on anemia, fibrotic disease, and cancer using proprietary expertise in HIF biology and ADC technology.

Strategic Profile

Pro stress-test →

The company completed a transformative strategic shift, concentrating on its lead asset FG-3246, an Antibody-Drug Conjugate (ADC) for prostate cancer. The sale of the China business for approximately $220 million extended the cash runway into 2028, providing a buffer to reach key clinical milestones.

Competitive Landscape

Pro stress-test →

FibroGen competes in the biopharmaceutical space against larger oncology and rare disease specialists. Its focus on first-in-class HIF inhibitors and ADC conjugates differentiates it from competitors like Agios Pharmaceuticals, Akebia Therapeutics, and other mid-cap biotech firms developing anemia and oncology therapeutics.

Industry Context

FibroGen, Inc. operates in Biopharmaceutical - Oncology and Hematology.

Key facts

Founded: 1993 · Headquarters: San Francisco, California · Revenue: $29.62 million

What the analysts stress-tested

The top findings that survived the multi-agent debate for FibroGen, Inc..

  • Q3 2025 net income exceeded $200 million following sale of China operations
  • Lead product Roxadustat has completed Phase III clinical development for anemia in chronic kidney disease in multiple geographies and Phase III for anemia related with myelodysplastic syndromes
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Completed sale of China operations for ~$220 million, extending cash runway to 2028
  • 2024Pamrevlumab pancreatic cancer trials failed primary endpoints; program terminated with workforce reduction
  • +1 moreTrack every material event for FibroGen, Inc. as it happens. Explore monitoring →
Get alerted when FibroGen, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

HIF inhibitors for anemiaCompeting HIF pathway modifiers for chronic kidney disease anemia→ADC oncology programsLarge-cap competitors with established ADC platforms in solid tumors→CTGF-targeting therapiesEarlier-stage programs targeting connective tissue growth factor pathway→

Compare FibroGen, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

FibroGen, Inc. operates in Biopharmaceutical - Oncology and Hematology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology and Hematology research →
NEW · MCP server

Ask your AI assistant about FibroGen, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare FibroGen, Inc. and its top competitor on Cyborg Score”
“What did FibroGen, Inc. do this quarter?”
“Is FibroGen, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does FibroGen, Inc. do?+
FibroGen, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company focuses on anemia, fibrotic disease, and cancer using proprieta...
What is FibroGen, Inc.'s Cyborg Score?+
FibroGen, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are FibroGen, Inc.'s main competitors?+
Named competitors include HIF inhibitors for anemia, ADC oncology programs, CTGF-targeting therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full FibroGen, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the FibroGen, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track FibroGen, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Oncology and Hematology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6FibroGen, Inc.